Desmopressin
approvedAlso known as: DDAVP, Minirin
Desmopressin (DDAVP, Minirin) is a synthetic analog of the antidiuretic hormone arginine vasopressin, with selective agonism at V2 receptors in the renal collecting ducts. This activation increases aquaporin-2 water channel insertion, enhancing water reabsorption and producing concentrated urine. Unlike native vasopressin, desmopressin has minimal V1a receptor activity, resulting in negligible vasoconstrictor or pressor effects. At higher doses, it also stimulates the release of von Willebrand factor and factor VIII from endothelial stores, which underlies its utility in certain bleeding disorders. Key research findings from over 4,200 PubMed-indexed studies confirm desmopressin’s efficacy in central diabetes insipidus by reducing polyuria and polydipsia, and in nocturnal enuresis by decreasing overnight urine production. In mild hemophilia A and von Willebrand disease (type 1), desmopressin transiently raises clotting factor levels, reducing bleeding risk during minor procedures. Its safety profile is well-established, though hyponatremia remains a notable risk, particularly in elderly patients or those with polydipsia, requiring careful fluid restriction monitoring. Clinically, desmopressin is approved for multiple indications across endocrinology, urology, and hematology. It is available in oral, intranasal, and injectable formulations, with dosing tailored to the condition. Its rapid onset and short half-life allow flexible use, but tachyphylaxis can occur with repeated dosing in bleeding disorders. Desmopressin remains a cornerstone therapy for central diabetes insipidus and nocturnal enuresis, while serving as a first-line hemostatic agent in select coagulopathies. For research purposes only — not medical advice.
Key data
C46H64N14O12S2Research & studies
Desmopressin may reduce mean wet nights per week versus placebo (MD -1.81, low-certainty evidence).; Desmopressin probably increases children achieving 14 consecutive dry nights versus placebo (RR 3.18, moderate-certainty evidence).; Desmopressin and alarm therapy may show little difference in achieving dry nights (RR 0.98, low-certainty evidence).; Combining desmopressin with alarm therapy may improve outcomes versus desmopressin alone (RR 1.26 for 14 dry nights, low-certainty evidence).
BIPSS accurately lateralized 76% of cases overall, with 71% for CRH and 79% for desmopressin (p=0.2).; For tumors <6 mm on MRI, accuracy was 75% with CRH and 90% with desmopressin (p=0.4).; IPSS achieved 100% accuracy in four cases with no lesion on preoperative MRI.; Desmopressin is an effective alternative to CRH for BIPSS lateralization, especially in challenging cases.
First-line aggressive treatments for monosymptomatic nocturnal enuresis are oral desmopressin or alarm therapy.; For desmopressin non-responders, reconfirm administration method and check for factors reducing efficacy.; If alarm therapy fails, the patient may be fundamentally unsuitable for this approach.; Promptly consider next treatment strategies in non-responders to keep patients motivated.
Desmopressin response cannot completely differentiate the various etiologies of Cushing syndrome.; Desmopressin is useful for confirming a pituitary source of ACTH excess during inferior petrosal sinus sampling.; Loss of desmopressin stimulatory effect after pituitary surgery can indicate adequate corticotroph tumor resection.; Desmopressin response may serve as a marker for risk of long-term postoperative recurrence.
Frequently asked questions
What is Desmopressin?
Desmopressin (DDAVP, Minirin) is a synthetic analog of the antidiuretic hormone arginine vasopressin, with selective agonism at V2 receptors in the renal collecting ducts. This activation increases aquaporin-2 water channel insertion, enhancing water reabsorption and producing concentrated urine. Unlike native vasopres
How does Desmopressin work?
Selective V2-receptor vasopressin analog that concentrates urine; used for diabetes insipidus, nocturnal enuresis, and bleeding disorders.
What is the research status of Desmopressin?
Desmopressin is currently classified as approved, with 4,239 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Desmopressin?
Desmopressin has a molecular weight of approximately 1069.2 g/mol (formula C46H64N14O12S2).
Related peptides
Nonapeptide posterior pituitary hormone driving uterine contraction and milk letdown; studied intranasally for social cognition.
GnRH agonist that suppresses gonadotropin and sex-steroid production after initial stimulation; used in prostate cancer, endometriosis, and precocious puberty.
Long-acting GnRH agonist that after initial flare downregulates pituitary receptors, suppressing sex hormones for prostate cancer and endometriosis.
Synthetic GnRH decapeptide that stimulates pituitary LH and FSH release; used diagnostically and to support gonadal function.
Build on Desmopressin data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key